carbamates has been researched along with Hypertension in 69 studies
Hypertension: Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The animal and human pharmacology of several new drugs (prazosin, trimazosin, pirbuterol, and carbazeran) useful in the treatment of congestive heart failure (CHF) is delineated in relation to the pharmacology of other agents employed for CHF management." | 6.15 | Comparative pharmacology and clinical efficacy of newer agents in treatment of heart failure. ( Baird, JR; Blackburn, KJ; Cambridge, D; Constantine, JW; Ghaly, MS; Hayden, ML; McIlhenny, HM; Moore, PF; Olukotun, AY; Pullman, LG; Salsburg, DS; Saxton, CA; Shevde, S; Taylor, CR, 1981) |
| "Alzheimer's disease patients with hypertension or other vascular risk factors have been shown to receive greater symptomatic benefits than patients with strictly Alzheimer's disease following short-term treatment with rivastigmine, an inhibitor of acetylcholinesterase and butyrylcholinesterase." | 5.10 | Potential long-term effects of rivastigmine on disease progression may be linked to drug effects on vascular changes in Alzheimer brains. ( Andrews, C; Erkinjuntti, T; Lane, R; Skoog, I, 2003) |
| "Hypertension induced hypoinsulinemia with concomitant lack of significant changes in glycemia, reduced intramyocardial glycogen content and increased pyruvate dehydrogenase (PDH) expression in the cardiac muscle." | 3.88 | The Endocannabinoid System Affects Myocardial Glucose Metabolism in the DOCA-Salt Model of Hypertension. ( Chabowski, A; Harasim-Symbor, E; Kasacka, I; Lewandowska, A; Malinowska, B; Polak, A, 2018) |
| "These results broadly support the literature showing that the cardiovascular effects of cannabinoids can be exaggerated in hypertension, but highlight the involvement of non-CB(1) receptor-mediated mechanisms in the actions of anandamide." | 3.75 | Acute hypertension reveals depressor and vasodilator effects of cannabinoids in conscious rats. ( Gardiner, SM; Ho, WS, 2009) |
| "We conclude that endocannabinoids tonically suppress cardiac contractility in hypertension and that enhancing the CB1-mediated cardiodepressor and vasodilator effects of endogenous anandamide by blocking its hydrolysis can normalize blood pressure." | 3.72 | Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. ( Bátkai, S; Bukoski, RD; Harvey-White, J; Kunos, G; Liu, J; Mackie, K; Offertáler, L; Osei-Hyiaman, D; Pacher, P; Radaeva, S; Rudd, MA, 2004) |
| "Cardiovascular adverse events (CVAEs) associated with BRAF inhibitors alone versus combination BRAF/MEK inhibitors are not fully understood." | 1.62 | Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Cross-sectional and longitudinal analysis using two large national registries. ( Al-Kindi, S; Barnholtz-Sloan, JS; de Lima, M; Dowlati, A; Fradley, MG; Guha, A; Gutierrez, JM; Jain, C; Jain, P; Lenihan, D; Oliveira, GH, 2021) |
| "Our study aimed to examine the effects of hypertension and the chronic administration of the fatty acid amide hydrolase (FAAH) inhibitor URB597 on vascular function and the endocannabinoid system in spontaneously hypertensive rats (SHR)." | 1.62 | Beneficial Changes in Rat Vascular Endocannabinoid System in Primary Hypertension and under Treatment with Chronic Inhibition of Fatty Acid Amide Hydrolase by URB597. ( Baranowska-Kuczko, M; Biernacki, M; Harasim-Symbor, E; Kasacka, I; Kloza, M; Kozłowska, H; Malinowska, B, 2021) |
| " The present study tested whether chronic administration of the fatty acid amide hydrolase (FAAH) inhibitor [3-(3-carbamoylphenyl) phenyl]N-cyclohexylcarbamate (URB597) to rats with primary hypertension (SHR) can modify redox balance and consequently brain phospholipid metabolism." | 1.56 | The FAAH Inhibitor URB597 Modulates Lipid Mediators in the Brain of Rats with Spontaneous Hypertension. ( Baranowska-Kuczko, M; Biernacki, M; Niklińska, GN; Skrzydlewska, E, 2020) |
| "The effect of chronic administration of [3-(3-carbamoylphenyl)phenyl] N-cyclohexylcarbamate (URB597), inhibitor of fatty acid amide hydrolase (FAAH) that hydrolyzes anandamide, on cross-talk between endocannabinoid system, oxidative status and pro-inflammatory factors in the liver of spontaneously hypertensive rats (SHRs) was investigated." | 1.51 | Long-term administration of fatty acid amide hydrolase inhibitor (URB597) to rats with spontaneous hypertension disturbs liver redox balance and phospholipid metabolism. ( Ambrożewicz, E; Biernacki, M; Gęgotek, A; Skrzydlewska, E; Toczek, M, 2019) |
| " The aim of this study was to compare the effect of chronic administration of URB597, the FAAH (fatty acid amide hydrolase) inhibitor, to rats with primary (SHRs) and secondary (DOCA-salt hypertensive rats) hypertension on electrical and physicochemical properties of kidney cells membranes." | 1.51 | Changes in physicochemical properties of kidney cells membrane as a consequence of hypertension and treatment of hypertensive rats with FAAH inhibitor. ( Dobrzyńska, I; Figaszewski, ZA; Skrzydlewska, E; Szachowicz-Petelska, B; Weresa, J, 2019) |
| "Hypertension affected cardiac and plasma endocannabinoid systems in a model-dependent manner: anandamide and 2-arachidonoylglycerol levels decreased in SHR and increased in DOCA-salt." | 1.48 | Hypertension and chronic inhibition of endocannabinoid degradation modify the endocannabinoid system and redox balance in rat heart and plasma. ( Biernacki, M; Jastrząb, A; Malinowska, B; Remiszewski, P; Skrzydlewska, E; Timoszuk, M; Toczek, M, 2018) |
| " The aim of our study was to examine the age-specific influence of the chronic administration of the FAAH inhibitor URB597 on blood pressure (BP), heart rate (HR) and cardiac and renal hypertrophy in hypertensive rats during two critical periods for the development of hypertension." | 1.43 | Age-specific influences of chronic administration of the fatty acid amide hydrolase inhibitor URB597 on cardiovascular parameters and organ hypertrophy in DOCA-salt hypertensive rats. ( Baranowska-Kuczko, M; Grzęda, E; Malinowska, B; Pędzińska-Betiuk, A; Toczek, M; Weresa, J, 2016) |
| " The aim of this study was to evaluate the effects of chronic administration of the fatty acid amide hydrolase (FAAH) inhibitor [3-(3-carbamoylphenyl)phenyl]N-cyclohexylcarbamate (URB597) on the endocannabinoid system and on the redox balance in the livers of DOCA-salt hypertensive rats." | 1.43 | Crosstalk between liver antioxidant and the endocannabinoid systems after chronic administration of the FAAH inhibitor, URB597, to hypertensive rats. ( Bielawska, K; Biernacki, M; Gęgotek, A; Skrzydlewska, E; Toczek, M; Łuczaj, W, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 41 (59.42) | 18.7374 |
| 1990's | 2 (2.90) | 18.2507 |
| 2000's | 6 (8.70) | 29.6817 |
| 2010's | 16 (23.19) | 24.3611 |
| 2020's | 4 (5.80) | 2.80 |
| Authors | Studies |
|---|---|
| Wiegand, J | 1 |
| Buggisch, P | 1 |
| Mauss, S | 1 |
| Boeker, KHW | 1 |
| Klinker, H | 1 |
| Müller, T | 1 |
| Günther, R | 1 |
| Serfert, Y | 1 |
| Manns, MP | 1 |
| Zeuzem, S | 1 |
| Berg, T | 1 |
| Hinrichsen, H | 1 |
| C-Registry, GH | 1 |
| Dobrzyńska, I | 2 |
| Szachowicz-Petelska, B | 2 |
| Pędzińska-Betiuk, A | 3 |
| Figaszewski, ZA | 2 |
| Skrzydlewska, E | 7 |
| Biernacki, M | 6 |
| Baranowska-Kuczko, M | 4 |
| Niklińska, GN | 1 |
| Guha, A | 1 |
| Jain, P | 1 |
| Fradley, MG | 1 |
| Lenihan, D | 1 |
| Gutierrez, JM | 1 |
| Jain, C | 1 |
| de Lima, M | 1 |
| Barnholtz-Sloan, JS | 1 |
| Oliveira, GH | 1 |
| Dowlati, A | 1 |
| Al-Kindi, S | 1 |
| Kozłowska, H | 2 |
| Kloza, M | 2 |
| Harasim-Symbor, E | 3 |
| Kasacka, I | 4 |
| Malinowska, B | 7 |
| Polak, A | 2 |
| Weresa, J | 3 |
| Chabowski, A | 2 |
| Lewandowska, A | 1 |
| Timoszuk, M | 1 |
| Toczek, M | 7 |
| Jastrząb, A | 1 |
| Remiszewski, P | 1 |
| Łuczaj, W | 2 |
| Jarocka-Karpowicz, I | 1 |
| Ambrożewicz, E | 2 |
| Gęgotek, A | 2 |
| Fretwell, LV | 1 |
| Woolard, J | 1 |
| Pombo, M | 1 |
| Olalla, J | 1 |
| Del Arco, A | 1 |
| De La Torre, J | 1 |
| Urdiales, D | 1 |
| Aguilar, A | 1 |
| Prada, JL | 1 |
| García-Alegría, J | 1 |
| Ruiz-Mateas, F | 1 |
| Schlicker, E | 1 |
| Grzęda, E | 2 |
| Karpińska, O | 1 |
| Harasim, E | 1 |
| Bielawska, K | 1 |
| Ho, WS | 1 |
| Gardiner, SM | 1 |
| Jepps, TA | 2 |
| Chadha, PS | 1 |
| Davis, AJ | 1 |
| Harhun, MI | 1 |
| Cockerill, GW | 1 |
| Olesen, SP | 2 |
| Hansen, RS | 1 |
| Greenwood, IA | 2 |
| Hopps, JJ | 1 |
| Dunn, WR | 1 |
| Randall, MD | 1 |
| Erkinjuntti, T | 2 |
| Skoog, I | 2 |
| Lane, R | 2 |
| Andrews, C | 2 |
| BOHENSKY, FB | 1 |
| PERRICONI, H | 1 |
| DEL RIO, CA | 1 |
| MAZZEI, CM | 1 |
| FRONTICELLI, G | 1 |
| MONTI, M | 1 |
| TUMIOTTO, G | 1 |
| FISHBACK, DB | 2 |
| CASTOR, LH | 1 |
| BAUCE, A | 1 |
| RIGHINI, G | 1 |
| MORDENTI, V | 1 |
| DEGRAFF, AC | 1 |
| LYON, AF | 2 |
| MASEKI, T | 1 |
| TSUCHIYA, T | 1 |
| IGUCHI, K | 1 |
| YAMASHITA, T | 1 |
| BALDRIGHI, G | 2 |
| FRIGERIO, G | 1 |
| TRONCONI, L | 2 |
| MASSONI, G | 1 |
| SCAPELLATO, L | 1 |
| BRANCATI, B | 1 |
| KAVELMAN, DA | 1 |
| LEWIS, JA | 1 |
| SANCHETTI, P | 1 |
| FAVERO, S | 1 |
| LONGARETTI, A | 1 |
| BELSITO, F | 1 |
| GERSHENSON, DA | 1 |
| ROEDIGER, PM | 1 |
| PUSCHAK, TB | 1 |
| HUTCHISON, JC | 1 |
| SCHWARTZ, W | 1 |
| D AMELIO, V | 1 |
| ANNOVI, G | 1 |
| MARMO, E | 1 |
| SARLUCA, F | 1 |
| LEONARDIS, G | 1 |
| SPLENDIANI, G | 1 |
| BELLUSCHI, A | 1 |
| VACCHINI, V | 1 |
| BERT, G | 1 |
| ANFOSSI, F | 2 |
| ANSELMINO, A | 1 |
| GAGNA, C | 1 |
| MATHIS, I | 1 |
| RUSCHENA, A | 1 |
| MIGHELI, B | 1 |
| CARTER, FS | 1 |
| Tayebati, SK | 1 |
| Di Tullio, MA | 1 |
| Amenta, F | 1 |
| Karki, P | 1 |
| Ansari, JA | 1 |
| Bhandary, S | 1 |
| Koirala, S | 1 |
| Bátkai, S | 1 |
| Pacher, P | 1 |
| Osei-Hyiaman, D | 1 |
| Radaeva, S | 1 |
| Liu, J | 1 |
| Harvey-White, J | 1 |
| Offertáler, L | 1 |
| Mackie, K | 1 |
| Rudd, MA | 1 |
| Bukoski, RD | 1 |
| Kunos, G | 1 |
| Belloni, L | 1 |
| Savioli, F | 1 |
| Natangelo, R | 1 |
| Ferrario, G | 1 |
| Taylor, CR | 1 |
| Baird, JR | 1 |
| Blackburn, KJ | 1 |
| Cambridge, D | 1 |
| Constantine, JW | 1 |
| Ghaly, MS | 1 |
| Hayden, ML | 1 |
| McIlhenny, HM | 1 |
| Moore, PF | 1 |
| Olukotun, AY | 1 |
| Pullman, LG | 1 |
| Salsburg, DS | 1 |
| Saxton, CA | 1 |
| Shevde, S | 1 |
| Futagawa, H | 1 |
| Kakinuma, Y | 1 |
| Takahashi, H | 1 |
| Tostes, RC | 1 |
| Storm, DS | 1 |
| Chi, DH | 1 |
| Webb, RC | 1 |
| Pfeffer, JM | 1 |
| Pfeffer, MA | 1 |
| Frohlich, ED | 1 |
| Rydén, L | 1 |
| Hjalmarson, A | 1 |
| Wasir, H | 1 |
| Werkö, L | 1 |
| Rasková, H | 1 |
| Gutová, M | 1 |
| Elis, J | 1 |
| Barcal, M | 1 |
| Janda, K | 1 |
| Huml, V | 1 |
| Vomastek, F | 1 |
| Vejvoda, B | 1 |
| Sibille, A | 1 |
| Ragni, N | 1 |
| Cadenelli, GP | 1 |
| Chesrow, EJ | 1 |
| Bernstein, M | 1 |
| Weiss, D | 1 |
| Marquardt, GH | 1 |
| Mangano, D | 1 |
| Iwaki, R | 1 |
| Kudo, Y | 1 |
| Ishiko, J | 1 |
| Irikura, T | 1 |
| Pavesi, V | 1 |
| Campus, G | 1 |
| Carroll, MN | 1 |
| Golinko, RJ | 1 |
| Dunst, M | 1 |
| René, HF | 1 |
| Ford, DH | 1 |
| Repetto, S | 1 |
| Rezzonico, A | 1 |
| Gervasini, N | 1 |
| Stanton, HC | 1 |
| White, JB | 1 |
| Vizioli, A | 1 |
| Ceino, A | 1 |
| Huong, BQ | 1 |
| Buu-Hoï, NP | 1 |
| Minh, VD | 1 |
| Man, BX | 1 |
| Guaraggi, A | 1 |
| Rossi, PL | 1 |
2 reviews available for carbamates and Hypertension
| Article | Year |
|---|---|
One man's side effect is another man's therapeutic opportunity: targeting Kv7 channels in smooth muscle disorders.
Topics: Animals; Anticonvulsants; Carbamates; Constipation; Female; Humans; Hypertension; KCNQ1 Potassium Ch | 2013 |
Comparative pharmacology and clinical efficacy of newer agents in treatment of heart failure.
Topics: Animals; Asthma; Carbamates; Cardiotonic Agents; Cardiovascular Agents; Clinical Trials as Topic; Dr | 1981 |
5 trials available for carbamates and Hypertension
| Article | Year |
|---|---|
Rivastigmine in patients with Alzheimer's disease and concurrent hypertension.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Double-Blind Method; Female; Humans; | 2002 |
Potential long-term effects of rivastigmine on disease progression may be linked to drug effects on vascular changes in Alzheimer brains.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Disease Progression; Female; Humans; | 2003 |
Comparative pharmacology and clinical efficacy of newer agents in treatment of heart failure.
Topics: Animals; Asthma; Carbamates; Cardiotonic Agents; Cardiovascular Agents; Clinical Trials as Topic; Dr | 1981 |
[Suitability of chemotherapy in early hypertension].
Topics: Carbamates; Clinical Trials as Topic; Humans; Hypertension; Hypnotics and Sedatives; Phytotherapy; P | 1967 |
Comparison of mebutamate, phenobarbital, and placebo in the treatment of mild essential hypertension.
Topics: Carbamates; Clinical Trials as Topic; Female; Humans; Hypertension; Male; Phenobarbital; Placebos | 1966 |
63 other studies available for carbamates and Hypertension
| Article | Year |
|---|---|
Hepatitis C therapy with direct antiviral agents in patients with advanced chronic kidney disease: real-world experience of the German Hepatitis C-Registry (Deutsches Hepatitis C-Register).
Topics: 2-Naphthylamine; Acute Disease; Adult; Aged; Anemia; Anilides; Antiviral Agents; Benzimidazoles; Car | 2019 |
Effects of hypertension and FAAH inhibitor treatment of rats with primary and secondary hypertension considering the physicochemical properties of erythrocytes.
Topics: Amidohydrolases; Animals; Benzamides; Carbamates; Disease Models, Animal; Erythrocyte Membrane; Hype | 2020 |
The FAAH Inhibitor URB597 Modulates Lipid Mediators in the Brain of Rats with Spontaneous Hypertension.
Topics: Animals; Arachidonic Acids; Benzamides; Brain; Carbamates; Disease Models, Animal; Endocannabinoids; | 2020 |
Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Cross-sectional and longitudinal analysis using two large national registries.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2021 |
Beneficial Changes in Rat Vascular Endocannabinoid System in Primary Hypertension and under Treatment with Chronic Inhibition of Fatty Acid Amide Hydrolase by URB597.
Topics: Acetylcholine; Amidohydrolases; Animals; Aorta; Arachidonic Acids; Benzamides; Carbamates; Endocanna | 2021 |
The effects of chronic FAAH inhibition on myocardial lipid metabolism in normotensive and DOCA-salt hypertensive rats.
Topics: Amidohydrolases; Animals; Benzamides; Blood Pressure; Carbamates; Chromatography, Gas; Chromatograph | 2017 |
The Endocannabinoid System Affects Myocardial Glucose Metabolism in the DOCA-Salt Model of Hypertension.
Topics: Animals; Benzamides; Blood Glucose; Carbamates; Desoxycorticosterone Acetate; Glucose; Glucose Trans | 2018 |
Hypertension and chronic inhibition of endocannabinoid degradation modify the endocannabinoid system and redox balance in rat heart and plasma.
Topics: Amidohydrolases; Animals; Arachidonic Acids; Benzamides; Carbamates; Desoxycorticosterone Acetate; E | 2018 |
The Effect of Long-Term Administration of Fatty Acid Amide Hydrolase Inhibitor URB597 on Oxidative Metabolism in the Heart of Rats with Primary and Secondary Hypertension.
Topics: Amidohydrolases; Animals; Benzamides; Carbamates; Desoxycorticosterone Acetate; Disease Models, Anim | 2018 |
Long-term administration of fatty acid amide hydrolase inhibitor (URB597) to rats with spontaneous hypertension disturbs liver redox balance and phospholipid metabolism.
Topics: Amidohydrolases; Animals; Benzamides; Carbamates; Endocannabinoids; Enzyme Inhibitors; Fatty Acids; | 2019 |
Changes in physicochemical properties of kidney cells membrane as a consequence of hypertension and treatment of hypertensive rats with FAAH inhibitor.
Topics: Amidohydrolases; Animals; Benzamides; Carbamates; Cell Membrane; Chromatography, High Pressure Liqui | 2019 |
Cardiovascular responses to retigabine in conscious rats--under normotensive and hypertensive conditions.
Topics: Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Animals; Antihypertensive Agents; Arr | 2013 |
Left ventricular hypertrophy detected by echocardiography in HIV-infected patients.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Carba | 2013 |
Enhanced function of inhibitory presynaptic cannabinoid CB1 receptors on sympathetic nerves of DOCA-salt hypertensive rats.
Topics: Animals; Benzamides; Blood Pressure; Cannabinoid Receptor Agonists; Cannabinoid Receptor Antagonists | 2015 |
Age-specific influences of chronic administration of the fatty acid amide hydrolase inhibitor URB597 on cardiovascular parameters and organ hypertrophy in DOCA-salt hypertensive rats.
Topics: Amidohydrolases; Animals; Benzamides; Blood Pressure; Carbamates; Desoxycorticosterone Acetate; Hear | 2016 |
Protective role of cannabinoid CB1 receptors and vascular effects of chronic administration of FAAH inhibitor URB597 in DOCA-salt hypertensive rats.
Topics: Amidohydrolases; Animals; Aorta; Arachidonic Acids; Benzamides; Blood Pressure; Capsaicin; Carbamate | 2016 |
Crosstalk between liver antioxidant and the endocannabinoid systems after chronic administration of the FAAH inhibitor, URB597, to hypertensive rats.
Topics: Amidohydrolases; Animals; Benzamides; Carbamates; Catalase; Desoxycorticosterone Acetate; Endocannab | 2016 |
Acute hypertension reveals depressor and vasodilator effects of cannabinoids in conscious rats.
Topics: Acute Disease; Amidohydrolases; Animals; Arachidonic Acids; Benzamides; Benzoxazines; Blood Pressure | 2009 |
Downregulation of Kv7.4 channel activity in primary and secondary hypertension.
Topics: Angiotensin II; Animals; Aorta, Thoracic; Blood Pressure; Carbamates; Down-Regulation; Hypertension; | 2011 |
Enhanced vasorelaxant effects of the endocannabinoid-like mediator, oleamide, in hypertension.
Topics: Amidohydrolases; Animals; Aorta; Benzamides; Biomimetic Materials; Cannabinoid Receptor Modulators; | 2012 |
Mebutamate, a new drug for the treatment of hypertension.
Topics: Anti-Anxiety Agents; Antihypertensive Agents; Antipsychotic Agents; Carbamates; Hypertension | 1962 |
[Methyl-dopa and mebutamate. Hypotensive action of guanethidine. Comparative study].
Topics: Anti-Anxiety Agents; Antihypertensive Agents; Carbamates; Dihydroxyphenylalanine; Guanethidine; Hype | 1963 |
[Mebutamate in the therapy of hypertensive states].
Topics: Antihypertensive Agents; Antipsychotic Agents; Carbamates; Humans; Hypertension | 1963 |
Effective hypertension therapy with least side effects: observations on mebutamate and hydrochlorothiazide.
Topics: Anti-Anxiety Agents; Antihypertensive Agents; Antipsychotic Agents; Carbamates; Humans; Hydrochlorot | 1963 |
[On the treatment of arterial hypertension with a combination of mebutamate, reserpine and hydralazine].
Topics: Anti-Anxiety Agents; Antihypertensive Agents; Antipsychotic Agents; Carbamates; Hydralazine; Hyperte | 1963 |
Mebutamate. Antihypertensive or tranquilizer?
Topics: Antihypertensive Agents; Carbamates; Humans; Hypertension; Tranquilizing Agents | 1963 |
[CLINICAL EFFECTS OF MEBUTAMATE (MEGA) IN ESSENTIAL HYPERTENSION].
Topics: Antihypertensive Agents; Carbamates; Essential Hypertension; Hypertension | 1963 |
[ON THE COMBINED PHARMACOLOGICAL TREATMENT OF ARTERIAL HYPERTENSION].
Topics: Antihypertensive Agents; Antipsychotic Agents; Carbamates; Humans; Hydralazine; Hypertension; Reserp | 1963 |
[MEBUTAMATE ASSOCIATIONS IN ANTIHYPERTENSIVE THERAPY].
Topics: Antihypertensive Agents; Antipsychotic Agents; Carbamates; Ethylenediamines; Humans; Hydralazine; Hy | 1963 |
CLINICAL EVALUATION OF A NEW ANTIHYPERTENSIVE AGENT: W583 (MEBUTAMATE).
Topics: Antihypertensive Agents; Blood Pressure; Blood Pressure Determination; Carbamates; Double-Blind Meth | 1963 |
[CLINICAL STUDY OF A NEW COMPLEX HYPOTENSIVE DRUG COMBINATION].
Topics: Antihypertensive Agents; Arteriosclerosis; Carbamates; Cerebrovascular Disorders; Coronary Disease; | 1963 |
[CLINICAL RESEARCH WITH A COMPOUND HYPOTENSIVE PREPARATION (MEBUTAMATE + 1-4 DIHYDRAZINOPHTHALAZINE + DIHYDROCHLOROTHIAZIDE + POTASSIUM)].
Topics: Antihypertensive Agents; Arteriosclerosis; Carbamates; Humans; Hydralazine; Hydrochlorothiazide; Hyp | 1963 |
MEBUTAMATE IN HYPERTENSION.
Topics: Anti-Anxiety Agents; Antihypertensive Agents; Antipsychotic Agents; Carbamates; Chlorothiazide; Hype | 1963 |
HYPERTENSION CONTROL; MEBUTAMATE AND HYDROCHLOROTHIAZIDE.
Topics: Anti-Anxiety Agents; Antihypertensive Agents; Carbamates; Geriatrics; Hydrochlorothiazide; Hypertens | 1964 |
MEBUTAMATE AND HYDROCHLOROTHIAZIDE IN HYPERTENSION.
Topics: Antihypertensive Agents; Arthritis; Arthritis, Rheumatoid; Blood Pressure Determination; Carbamates; | 1964 |
[TREATMENT WITH MEBUTAMATE (AN ANTIHYPERTENSIVE WITH CENTRAL ACTION) OF MENTAL PATIENTS WITH HYPERTENSIVE MANIFESTATIONS].
Topics: Alcoholism; Antihypertensive Agents; Anxiety; Bipolar Disorder; Carbamates; Dementia; Epilepsy; Huma | 1963 |
[INTERACTIONS BETWEEN GAMMA-AMINO-BUTYRIC ACID AND MEBUTAMATE AND THEIR REPERCUSSIONS IN ANTIHYPERTENSIVE THERAPY].
Topics: Aminobutyrates; Antihypertensive Agents; Blood Pressure; Blood Pressure Determination; Butyric Acid; | 1964 |
[PREOPERATIVE TREATMENT OF THE HYPERTENSIVE PATIENT WITH MEBUTAMATE].
Topics: Antihypertensive Agents; Carbamates; Humans; Hypertension; Preoperative Care; Surgical Procedures, O | 1964 |
[CLINICAL EVALUATION OF A PHARMACOLOGIC ASSOCIATION WITH HYPOTENSIVE ACTION].
Topics: Antihypertensive Agents; Biomedical Research; Carbamates; Drug Therapy; Electric Impedance; Humans; | 1964 |
[ACTION OF MEBUTAMATE ON RENAL CIRCULATION].
Topics: Antihypertensive Agents; Blood Circulation; Carbamates; Humans; Hypertension; Kidney; Pharmacology; | 1964 |
COMPARATIVE EFFICACY OF MEBUTAMATE COMBINED WITH HYDROCHLOROTHIAZIDE IN ESSENTIAL HYPERTENSION.
Topics: Antihypertensive Agents; Carbamates; Drug Therapy; Essential Hypertension; Hydrochlorothiazide; Hype | 1965 |
Effect of treatment with the cholinesterase inhibitor rivastigmine on vesicular acetylcholine transporter and choline acetyltransferase in rat brain.
Topics: Animals; Blood Pressure; Brain; Brain Chemistry; Carbamates; Choline O-Acetyltransferase; Cholineste | 2004 |
Cardiac and electrocardiographical manifestations of acute organophosphate poisoning.
Topics: Acute Disease; Adolescent; Adult; Arrhythmias, Cardiac; Carbamates; Critical Care; Electrocardiograp | 2004 |
Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension.
Topics: Amidohydrolases; Angiotensin II; Animals; Arachidonic Acids; Benzamides; Benzyl Compounds; Blood Pre | 2004 |
[Experience in hypotensive treatment with the association of mebutamate and gamma-aminobutyric acid].
Topics: Adult; Aged; Aminobutyrates; Carbamates; Female; Humans; Hypertension; Male; Middle Aged | 1967 |
[Contribution to anti-hypertensive therapy with a drug combination].
Topics: Aged; Carbamates; Female; Humans; Hydralazine; Hydrochlorothiazide; Hypertension; Male; Middle Aged; | 1967 |
Cardiovascular collapse through non-cholinergic mechanism after intravenous injection of N-methylcarbamate insecticide in rabbits.
Topics: Animals; Blood Pressure; Carbamates; Cholinesterase Inhibitors; Electrocardiography; Hypertension; I | 1997 |
Intracellular calcium stores and oscillatory contractions in arteries from genetically hypertensive rats.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl e | 1996 |
Hemodynamic effects of mebutamate in spontaneously hypertensive rats.
Topics: Animals; Blood Pressure; Carbamates; Cardiac Output; Female; Heart Rate; Hemodynamics; Hypertension; | 1975 |
Effects of a long-acting antiarrhythmic agent--QX-572--on therapy resistant ventricular tachyarrhythmias.
Topics: Acute Disease; Adult; Aged; Ajmaline; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Blood Pressure; | 1974 |
Fluorescein circulation time and the treatment of hypertension in the aged.
Topics: Adult; Age Factors; Aged; Blood Circulation Time; Blood Pressure; Carbamates; Ethacrynic Acid; Femal | 1973 |
[Clinical trial of a new drug with hypotensive action].
Topics: Aged; Benzothiadiazines; Carbamates; Drug Synergism; Female; Heterocyclic Compounds; Humans; Hyperte | 1971 |
[On a new hypotensive pharmacological association in pregnancy with hypertension].
Topics: Adult; Antihypertensive Agents; Blood Pressure; Carbamates; Creatinine; Electrolytes; Female; Humans | 1971 |
[Anti-hypertensive therapy in geriatrics].
Topics: Age Factors; Aged; Antihypertensive Agents; Carbamates; Drug Synergism; Female; Humans; Hydrazines; | 1970 |
[Differences on blood pressure responses to drugs in hypertensive and normotensive rats. (1)].
Topics: Animals; Atropine; Azoles; Blood Pressure; Body Weight; Caffeine; Carbamates; Chlorothiazide; Diuret | 1967 |
[Results of hypotensive treatment in a hospital environment].
Topics: Adult; Aged; Arteriosclerosis; Carbamates; Female; Humans; Hydralazine; Hydrochlorothiazide; Hyperte | 1968 |
CNS-evoked coronary changes and cardiac arrhythmias--anti-arrhythmic properties of mebutamate.
Topics: Animals; Arrhythmias, Cardiac; Carbamates; Central Nervous System Diseases; Dogs; Electric Stimulati | 1968 |
[Considerations on ambulatory therapy in a group of hypertensive patients].
Topics: Adult; Aged; Ambulatory Care; Carbamates; Female; Guanethidine; Humans; Hydralazine; Hydrochlorothia | 1969 |
Hypotensive actions of drugs on unanesthetized normotensive and "metacorticoid" hypertensive rats determined by a direct recording technique.
Topics: Animals; Antihypertensive Agents; Carbamates; Chlorisondamine; Desoxycorticosterone; Diazoxide; Guan | 1965 |
[Clinical trials of a new antihypertensive drug association in aged subjects. Behavior of the electrolyte pattern].
Topics: Aged; Carbamates; Electrolytes; Humans; Hydralazine; Hydrochlorothiazide; Hypertension; Potassium Ch | 1966 |
Evaluation of mebutamate in the treatment of hypertension in Vietnam.
Topics: Adult; Aged; Blood Pressure Determination; Carbamates; Female; Humans; Hypertension; Male; Middle Ag | 1966 |
[Research on the antihypertensive effect induced by the mebutamate-GABA (gamma-aminobutyric acid) combination in essential hypertension].
Topics: Aminobutyrates; Carbamates; Humans; Hypertension | 1966 |
[On the antihypertensive activity of some drugs alone or in various associations].
Topics: Adult; Aged; Antihypertensive Agents; Arteriosclerosis; Carbamates; Female; Humans; Hydrazines; Hydr | 1966 |